Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANZ 1103 (SOLACE) - Patients with metastatic BRCA-associated breast cancer, triple negative breast cancer or serous ovarian cancer receiving Olaparib (a PARP inhibitor) in combination with metronomic cyclophosphamide in a Phase I study to determine the maximum tolerated dose of this treatment combination

Trial Profile

ANZ 1103 (SOLACE) - Patients with metastatic BRCA-associated breast cancer, triple negative breast cancer or serous ovarian cancer receiving Olaparib (a PARP inhibitor) in combination with metronomic cyclophosphamide in a Phase I study to determine the maximum tolerated dose of this treatment combination

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms SOLACE
  • Most Recent Events

    • 25 Mar 2021 History page of this specific record has an error in opening so as of now I have added the bundle received date as an event date for change in planned end date from 30 Mar 2018 to 1 Apr 2019. Kindly update in the future
    • 19 Mar 2019 Planned End Date changed from 30 Mar 2018 to 1 Apr 2019.
    • 17 Jan 2019 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top